<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02400424</url>
  </required_header>
  <id_info>
    <org_study_id>GFPC 01-14</org_study_id>
    <nct_id>NCT02400424</nct_id>
  </id_info>
  <brief_title>Study of the Efficacy of SBRT on Unresectable Peripheral Primary Tumor</brief_title>
  <acronym>GFPC_01-14</acronym>
  <official_title>Multicenter Prospective Study of the Efficacy of Stereotactic Lung Radiation Therapy After Concomitant Radio-chemotherapy for Unresectable Stage III Non-small Cell Lung Carcinoma (NSCLC) With Peripheral Primary Tumor.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Leon Berard</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Leon Berard</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy of stereotactic lung radiation therapy
      after concomitant radiochemotherapy for unresectable stage III non-small cell lung carcinoma
      (NSCLC) with peripheral primary tumor.

      Evaluate in terms of local control rate at 6 months the addition of stereotactic radiotherapy
      after concurrent chemoradiotherapy in the treatment of mediastinal non-resectable stage III
      NSCLC having a peripheral primary tumor.

      The number of patients required in this multicenter prospective study is 70.

      This is a prospective, multicenter, non comparative and non randomized study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Stereotactic radiotherapy or SBRT (Body Stereotactic Radiation Therapy) allows to irradiate
      with high dose limited lesions size with a local control surrounding of 80-98% and with a low
      level of toxicity.

      We propose to realize a classic concomitant RT-CT for mediastinal irradiation and combine
      this treatment with stereotactic RT for peripheral primary tumor.

      The estimated inclusion period is approximately 3 years.

      Follow-up duration for each patient is 2 years. The duration of the research is 5 years.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Anticipated">January 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Local control rate</measure>
    <time_frame>6 months after the end of SBRT</time_frame>
    <description>According to RECIST v1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>From date of inclusion until the date of death from any cause, assessed up to 24 months after the end of SBRT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>From date of inclusion until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months after the end of SBRT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety (adverse events, assessed using the NCI-CTCAE v4 grading scale)</measure>
    <time_frame>Up to 2 years after the end of SBRT</time_frame>
    <description>Incidence of adverse events, assessed using the NCI-CTCAE v4 grading scale</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Non-small-cell Lung Carcinoma</condition>
  <arm_group>
    <arm_group_label>SBRT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study treatment = SBRT for peripheral primary tumor.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>SBRT</intervention_name>
    <description>54 Gy in 3 fractions D1-D3-D5. SBRT should be started within 3 to 4 weeks after the end of radiochemotheray (RT-CT).</description>
    <arm_group_label>SBRT</arm_group_label>
    <other_name>Stereotactic body radiation therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years ≤ Age ≤ 75 years

          -  PS ECOG 0 or 1

          -  Histologically proven NSCLC

          -  Unresectable stage III: T1 or T2 or T3 ≤ 5 cm AND N2 or N3 (only contralateral
             mediastinum or homolateral supraclavicular).

          -  Peripheral primary tumor ≥ 1 cm and ≤ 5 cm

          -  Possible concomitant chemoradiotherapy : 1 cure induction and 3 concomitant cycles of
             chemotherapy with cisplatin and Navelbine ® and 3D conformal radiotherapy delivering
             66 Gy in 33 fractions to the mediastinal lymph node involvement without treating the
             peripheral tumor.

          -  Adequate biological parameters

          -  Forced expiratory volume (FEV) ≥1 liter or ≥ 30% of the theoretical value

          -  Patient covered by a health insurance scheme

          -  Signed informed consent

        Exclusion Criteria:

          -  SCLC or large cell neuroendocrine carcinoma

          -  Metastatic disease

          -  Stage IVa

          -  Pregnant or breast-feeding women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Isabelle IM Martel Lafay, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Center Leon Berard</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ellen Blanc</last_name>
    <phone>+33 (0)4 78 78 29 67</phone>
    <email>ellen.blanc@lyon.unicancer.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre Leon Berard</name>
      <address>
        <city>Lyon</city>
        <zip>69373 cedex 08</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ellen BLANC</last_name>
      <phone>04 78 78 29 67</phone>
      <email>ellen.blanc@lyon.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Isabelle IM Martel Lafay, Investigator</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Nord-Ouest</name>
      <address>
        <city>Villefranche</city>
        <zip>69655</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Lionel FALCHERO, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 11, 2015</study_first_submitted>
  <study_first_submitted_qc>March 26, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 27, 2015</study_first_posted>
  <last_update_submitted>February 27, 2018</last_update_submitted>
  <last_update_submitted_qc>February 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Stereotactic lung radiation therapy</keyword>
  <keyword>Radiochemotherapy</keyword>
  <keyword>Unresectable stage III Non-Small Cell lung Carcinoma</keyword>
  <keyword>Peripheral primary tumor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

